about
NK Cell Influence on the Outcome of Primary Epstein-Barr Virus InfectionWhole blood gene expression in adolescent chronic fatigue syndrome: an exploratory cross-sectional study suggesting altered B cell differentiation and survival.A Temporal Proteomic Map of Epstein-Barr Virus Lytic Replication in B Cells.Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.NKG2A-Expressing Natural Killer Cells Dominate the Response to Autologous Lymphoblastoid Cells Infected with Epstein-Barr Virus.Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells.Epigenetics and Genetics of Viral Latency.Current Trends and Alternative Scenarios in EBV Research.Human immunity against EBV-lessons from the clinic.Known unknowns: how might the persistent herpesvirome shape immunity and aging?Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.EBV Infection Empowers Human B Cells for Autoimmunity: Role of Autophagy and Relevance to Multiple Sclerosis.Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease.Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential.The Role of Fungi in the Etiology of Multiple Sclerosis.Transforming growth factor beta (TGF-β) in adolescent chronic fatigue syndrome.EBV and Apoptosis: The Viral Master Regulator of Cell Fate?Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells.Beta and Gamma Human Herpesviruses: Agonistic and Antagonistic Interactions with the Host Immune System.EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts.Differential DNA methylation profiles of human B lymphocytes and Epstein-Barr virus-immortalized B lymphocytes.TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.The Immunomodulatory Capacity of an Epstein-Barr Virus Abortive Lytic Cycle: Potential Contribution to Viral Tumorigenesis.Impaired Control of Epstein-Barr Virus Infection in B-Cell Expansion with NF-κB and T-Cell Anergy Disease.An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse modelDefective (interfering) viral genomes re-explored: impact on antiviral immunity and virus persistencePARP1 Stabilizes CTCF Binding and Chromatin Structure To Maintain Epstein-Barr Virus Latency TypeProteome-wide analysis of CD8+ T cell responses to EBV reveals differences between primary and persistent infectionEpstein-Barr Virus-Associated Malignancies: Roles of Viral Oncoproteins in Carcinogenesis
P2860
Q28069456-7A19A2B5-D5FC-44CF-93FB-C852A91BD403Q33660262-6BED4899-87BC-468A-A838-C4E8D85938B8Q33734376-D9E807BD-C252-4F98-9190-38C9218A03A2Q33842381-83E7D30C-42BD-4E69-B904-725A849C775CQ37503717-58AFA010-55C7-4D7B-8B15-811A1AB8764CQ38768957-CB6B7993-BF16-483E-8A2E-7D408E0A7806Q38833222-7268B80E-6870-43EF-86D8-64240C2D7181Q39016336-6B18CB57-3BA7-45A0-BDDC-9FB8B9AEF2B3Q39097082-071CB796-2F74-4217-B274-3B6071279C57Q40093358-44AE7A67-A3BD-45D5-970D-6E6D8040A1E3Q40175806-08E56DF9-5895-474F-A32D-4CEC6F645394Q40181000-74333D50-CFA7-4B47-B320-7C5138E603EBQ40269570-7483E878-4E24-482C-B506-ED4401F66E3DQ40375799-39663573-9666-41EF-A4DC-D2968610E745Q45967285-EC757DA1-2ED4-4231-9F5C-B4B3C7B6336AQ47107793-E9A69687-0593-4C71-AD8B-6853194187F0Q47117102-2D458867-49D3-4858-8898-DAD92073869CQ47546882-DA20FA99-DAA5-4E8F-9046-BCE65E7A66D9Q47550811-FD6AE152-C537-4738-B9B6-435242A0F0FEQ51735191-548DED5A-C961-4C49-9AFF-3659E967D185Q52653163-D5C95C3B-891C-4803-BD94-49BE954439C5Q52691571-0D1AD8D8-BEDD-46EA-AB28-4C1E45099E4DQ54245037-21D7C45C-BF85-4DF7-AD68-EC7A06618F85Q55265317-6EA32F01-CBCC-4CAF-941D-119310D5FB8AQ57025486-C69EFEFE-DA5D-4E41-8918-10E35F5E968AQ57406999-27050DAE-FC80-4A4B-9C87-F59B44122607Q58693148-02E46180-4A30-4E32-A05F-39BCF6EDA2A1Q58699977-FB6CD997-4B9C-4B1C-8969-7BC6E7960073Q58803477-D14BA960-5D78-41CB-A335-0D40C795C9B6
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
EBV Persistence--Introducing the Virus.
@en
type
label
EBV Persistence--Introducing the Virus.
@en
prefLabel
EBV Persistence--Introducing the Virus.
@en
P2860
P1476
EBV Persistence--Introducing the Virus.
@en
P2093
David A Thorley-Lawson
P2860
P304
P356
10.1007/978-3-319-22822-8_8
P577
2015-01-01T00:00:00Z